New FDA guidance could elevate pharma's biosimilar market [Yahoo! Finance]
Cardinal Health, Inc. (CAH)
Last cardinal health, inc. earnings: 2/6 06:55 am
Check Earnings Report
US:NYSE Investor Relations:
ir.cardinalhealth.com/home
Company Research
Source: Yahoo! Finance
Since the FDA approved the first biosimilar 11 years ago, more than 80 biosimilars for various brand-name drugs have been given the go-ahead, reflecting major shifts in regulatory and industry priorities in the biologic arena. Now, the agency is paving the way for more approvals, hoping the smoother road will introduce competition and lower prices for consumers. This week, the FDA issued draft guidance that, in some cases, would lower the bar for biosimilar testing, allowing companies to develop copycat versions of biologic blockbusters for potentially half the R&D cost Biosimilars aren't easy to make. Unlike small molecules, which can be recreated using a chemical recipe, biologics and biosimilars are developed with live organisms. Even if a brand-name biologic is well established in the market, biosimilars need to be developed from the ground up and proven to be comparable — and at best interchangeable — with the original. Comparative studies alone can take up to three years
Show less
Read more
Impact Snapshot
Event Time:
CAH
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CAH alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CAH alerts
High impacting Cardinal Health, Inc. news events
Weekly update
A roundup of the hottest topics
CAH
News
- CAH's Pharma Segment Gains 19% in Q2'26: Is the Growth Sustainable? [Yahoo! Finance]Yahoo! Finance
- Is Cardinal Health Stock Outperforming the Dow? [Yahoo! Finance]Yahoo! Finance
- Can Specialty Momentum Push CAH's Earnings Growth Beyond 25% in FY26? [Yahoo! Finance]Yahoo! Finance
- Cardinal Health, Inc. (CAH) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- Cardinal Health (CAH) had its "outperform" rating reaffirmed by Leerink Partners.MarketBeat
CAH
Earnings
- 2/5/26 - Beat
CAH
Sec Filings
- 3/5/26 - Form 8-K
- 3/3/26 - Form 4
- 2/27/26 - Form 144
- CAH's page on the SEC website